Photon-emitting Brachytherapy Sources Research Articles

Supplement to the 2004 update of the AAPM Task Group No. 43 Report

Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical use as of January 10, 2005, and are posted on the Joint AAPM/RPC Brachytherapy Seed Registry. Consequently, the AAPM has prepared this supplement to the 2004 AAPM TG-43 update. This paper presents the AAPM-approved consensus datasets for these sources, and includes the following 125I sources: Amersham model 6733, Draximage model LS-1, Implant Sciences model 3500, IBt model 1251L, IsoAid model IAI-125A, Mentor model SL-125/ SH-125, and SourceTech Medical model STM1251. The Best Medical model 2335 103Pd source is also included. While the methodology used to determine these data sets is identical to that published in the AAPM TG-43U1 report, additional information and discussion are presented here on some questions that arose since the publication of the TG-43U1 report. Specifically, details of interpolation and extrapolation methods are described further, new methodologies are recommended, and example calculations are provided. Despite these changes, additions, and clarifications, the overall methodology, the procedures for developing consensus data sets, and the dose calculation formalism largely remain the same as in the TG-43U1 report. Thus, the AAPM recommends that the consensus data sets and resultant source-specific dose-rate distributions included in this supplement be adopted by all end users for clinical treatment planning of low-energy photon-emitting brachytherapy sources. Adoption of these recommendations may result in changes to patient dose calculations, and these changes should be carefully evaluated and reviewed with the radiation oncologist prior to implementation of the current protocol.

TU-EE-A1-03: Determining the Air-Kerma Strength of 1cm Coiled Brachytherapy Sources

Purpose: To show the ability of a large-volume free-air chamber to experimentally determine the air-kerma strength of a new 1cm 103Pd coiled brachytherapy sources and show its potential for determining the air-kerma strength of longer (2–6cm) coiled sources. Method and Materials: A Variable Aperture Free-Air Chamber (VAFAC) has been constructed for making air-kerma rate measurements of low-energy photon-emitting brachytherapy sources with photon energies up to 70 keV. The VAFAC has been used to determine the air-kerma strength of 1cm coiled brachytherapy sources. The present US air-kerma strength standard for low dose rate (LDR) brachytherapy sources is the National Institute of Standards and Technology Wide-Angle Free-Air Chamber (NIST WAFAC). The results obtained with the VAFAC were compared to air-kerma strengths determined with an Accredited Dosimetry Calibration Laboratory (ADCL) well ionization chamber (traceable to the NIST WAFAC) and direct measurement in the NIST WAFAC. At present, the WAFAC is unable to measure the air-kerma rate of the coiled sources longer than 1cm due to its geometric limitations. The VAFAC does not have the same geometric limitations as the NIST WAFAC, which extends its capabilities to measure sources up to 6cm in length. Results: It has been shown that air-kerma strengths determined for three 1cm length coils with the VAFAC are within 1% agreement with both an ADCL well ionization chamber and NIST WAFAC values. Conclusion: This work shows that the VAFAC can accurately determine the air-kerma strength of 1cm 103Pd coiled brachytherapy sources. It also shows the ability of the VAFAC to measure sources up to 6cm in length, a feat which was previously impossible due to the limitations of the NIST WAFAC. Conflict of Interest: Research sponsored by RadioMed Corporation.

Interstitial brachytherapy dosimetry update

In March 2004, the American Association of Physicists in Medicine (AAPM) published an update to the AAPM Task Group No. 43 Report (TG-43) which was initially published in 1995. This update was pursued primarily due to the marked increase in permanent implantation of low-energy photon-emitting brachytherapy sources in the United States over the past decade, and clinical rationale for the need of accurate dosimetry in the implementation of interstitial brachytherapy. Additionally, there were substantial improvements in the brachytherapy dosimetry formalism, accuracy of related parameters and methods for determining these parameters. With salient background, these improvements are discussed in the context of radiation dosimetry. As an example, the impact of this update on the administered dose is assessed for the model 200 (103)Pd brachytherapy source.

Progress on the supplement to the 2004 update of the AAPM Task Group No. 43 Report

Purpose: Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (AAPM TG-43Ul), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical use as of January 10, 2005, and are posted on the Joint AAPM/RPC Brachytherapy Seed Registry. This work is a presentation of a work-in-progress at the AAPM to determine consensus brachytherapy dosimetry parameters.

Polymer gel dosimetry close to an 125I interstitial brachytherapy seed

Despite its advantages, the polymer gel–magnetic resonance imaging (MRI) method has not, as yet, been successfully employed in dosimetry of low energy/low dose rate photon-emitting brachytherapy sources such as 125I or 103Pd interstitial seeds. In the present work, two commercially available 125I seed sources, each of approximately 0.5 U, were positioned at two different locations of a polymer gel filled vial. The gel vial was MR scanned with the sources in place 19 and 36 days after seed implantation. Calibration curves were acquired from the coupling of MRI measurements with accurate Monte Carlo dose calculations obtained simulating the exact experimental setup geometry and materials. The obtained gel response data imply that while linearity of response is sustained, sensitivity (calibration curve slope) is significantly increased (approximately 60%) compared to its typical value for the 192Ir (or 60Co and 6 MV LINAC) photon energies. Water equivalence and relative energy response corrections of the gel cannot account for more than 3–4% of this increase, which, therefore, has to be mainly attributed to physicochemical processes related to the low dose rate of the sources and the associated prolonged irradiation time. The calibration data obtained from one 125I source were used to provide absolute dosimetry results for the other 125I source, which were found to agree with corresponding Monte Carlo calculations within experimental uncertainties. It is therefore suggested that, regardless of the underlying factors accounting for the gel dose response to 125I irradiations, polymer gel dosimetry of new 125I or 103Pd sources should be carried out as originally proposed by Heard and Ibbot (2004 J. Phys.: Conf. Ser. 3 221–3), i.e., by irradiating the same gel sample with the new low dose rate source, as well as with a well-characterized low dose rate source which will provide the dose calibration curve for the same irradiation conditions.

Improved radial dose function estimation using current version MCNP Monte-Carlo simulation: Model 6711 and ISC3500 125I brachytherapy sources

Improved cross-sections in a new version of the Monte-Carlo N-particle (MCNP) code may eliminate discrepancies between radial dose functions (as defined by American Association of Physicists in Medicine Task Group 43) derived from Monte-Carlo simulations of low-energy photon-emitting brachytherapy sources and those from measurements on the same sources with thermoluminescent dosimeters. This is demonstrated for two 125I brachytherapy seed models, the Implant Sciences Model ISC3500 (I-Plant) and the Amersham Health Model 6711, by simulating their radial dose functions with two versions of MCNP, 4c2 and 5.

Procedures for establishing and maintaining consistent air-kerma strength standards for low-energy, photon-emitting brachytherapy sources: recommendations of the Calibration Laboratory Accreditation Subcommittee of the American Association of Physicists in Medicine.

Low dose rate brachytherapy is being used extensively for the treatment of prostate cancer. As of September 2003, there are a total of thirteen 125I and seven 103Pd sources that have calibrations from the National Institute of Standards and Technology (NIST) and the Accredited Dosimetry Calibration Laboratories (ADCLs) of the American Association of Physicists in Medicine (AAPM). The dosimetry standards for these sources are traceable to the NIST wide-angle free-air chamber. Procedures have been developed by the AAPM Calibration Laboratory Accreditation Subcommittee to standardize quality assurance and calibration, and to maintain the dosimetric traceability of these sources to ensure accurate clinical dosimetry. A description of these procedures is provided to the clinical users for traceability purposes as well as to provide guidance to the manufacturers of brachytherapy sources and ADCLs with regard to these procedures.

Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations

Since publication of the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report in 1995 (TG-43), both the utilization of permanent source implantation and the number of low-energy interstitial brachytherapy source models commercially available have dramatically increased. In addition, the National Institute of Standards and Technology has introduced a new primary standard of air-kerma strength, and the brachytherapy dosimetry literature has grown substantially, documenting both improved dosimetry methodologies and dosimetric characterization of particular source models. In response to these advances, the AAPM Low-energy Interstitial Brachytherapy Dosimetry subcommittee (LIBD) herein presents an update of the TG-43 protocol for calculation of dose-rate distributions around photon-emitting brachytherapy sources. The updated protocol (TG-43U1) includes (a) a revised definition of air-kerma strength; (b) elimination of apparent activity for specification of source strength; (c) elimination of the anisotropy constant in favor of the distance-dependent one-dimensional anisotropy function; (d) guidance on extrapolating tabulated TG-43 parameters to longer and shorter distances; and (e) correction for minor inconsistencies and omissions in the original protocol and its implementation. Among the corrections are consistent guidelines for use of point- and line-source geometry functions. In addition, this report recommends a unified approach to comparing reference dose distributions derived from different investigators to develop a single critically evaluated consensus dataset as well as guidelines for performing and describing future theoretical and experimental single-source dosimetry studies. Finally, the report includes consensus datasets, in the form of dose-rate constants, radial dose functions, and one-dimensional (1D) and two-dimensional (2D) anisotropy functions, for all low-energy brachytherapy source models that met the AAPM dosimetric prerequisites [Med. Phys. 25, 2269 (1998)] as of July 15, 2001. These include the following 125I sources: Amersham Health models 6702 and 6711, Best Medical model 2301, North American Scientific Inc. (NASI) model MED3631-A/M, Bebig/Theragenics model I25.S06, and the Imagyn Medical Technologies Inc. isostar model IS-12501. The 103Pd sources included are the Theragenics Corporation model 200 and NASI model MED3633. The AAPM recommends that the revised dose-calculation protocol and revised source-specific dose-rate distributions be adopted by all end users for clinical treatment planning of low energy brachytherapy interstitial sources. Depending upon the dose-calculation protocol and parameters currently used by individual physicists, adoption of this protocol may result in changes to patient dose calculations. These changes should be carefully evaluated and reviewed with the radiation oncologist preceding implementation of the current protocol.

Monte Carlo-aided dosimetry of the new Bebig IsoSeed 103Pd interstitial brachytherapy seed.

A new model 103Pd interstitial brachytherapy source, the IsoSeed 103Pd, was recently introduced by Bebig Isotopentechnik und Umweltdiagnostik GmbH for permanent implant applications. This study presents the first quantitative theoretical study of the seed's dosimetric quantities. Monte Carlo photon transport (MCPT) simulation techniques have been used to evaluate the dose-rate distributions around the model IsoSeed 103Pd source in liquid water and air phantoms. These results have been used to calculate and tabulate the anisotropy function, F(r, theta), radial dose function, g(r), and anisotropy factors, phi(r), and dose-rate constant as defined by AAPM Task Group 43 (TG-43) Report. Cartesian "away" and "along" tables, giving the dose rates per unit air-kerma strength in water in the range 0.1-3 cm distance around the seed have also been tabulated. The dose-rate constant, lambda, was evaluated by simulating the wide-angle, free-air chamber (WAFAC) calibration geometry recently implemented by NIST (National Institute of Standards and Technology) to realize the primary standard of air-kerma strength (SK,N99) for low-energy photon-emitting brachytherapy sources. The dose-rate constant has been found to be lambda=0.660+/-0.017 in units of dose-rate per unit air-kerma strength (cGy x h(-1) x U(-1)).

A position-sensitive superheated emulsion chamber for three-dimensional photon dosimetry

A position-sensitive detector chamber is introduced for the three-dimensional (3D) dosimetry of photon-emitting brachytherapy sources. The detector is based on an extremely fine suspension of monochloropentafluoroethane droplets emulsified in a gel. The droplets are highly superheated at room temperature and their evaporation can be triggered by photon interactions, leading to the formation of microscopic bubbles. Thus, when photon-emitting brachytherapy sources are inserted into the detector, bubble distributions form around them, enabling visualization of the radiation field. The tissue-equivalent emulsifier gel is highly viscous and keeps the bubbles immobilized at the location of their formation. Bubbles can then be imaged by nuclear magnetic resonance or optical scanning techniques. After the imaging, the detector can be pressurized in order to recondense the bubbles to the liquid phase. In a few minutes, the device is annealed and ready to be used again for repeated measurements improving the counting statistics. The photon sensitivity of the monochloropentafluoroethane droplets was determined with highly filtered, quasi-monochromatic x-ray beams and radionuclide sources. The air-kerma response presents a broad maximum at low energies, due to the relatively high effective atomic number of the halocarbon molecule. A prototype chamber was built and successfully tested: bubble distributions deriving from the insertion of a source were imaged by means of a slice-selective 3D gradient-echo technique. These experiments confirm the potential and viability of this new approach to 3D photon dosimetry.